Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial

키워드

참고문헌 (39)

1. Spijker J, "Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)", Acta Psychiatr Scand, 110, pp.208~214 (2004)
2. Russo M, "Measuring cognitive function in MDD : emerging assessment tools", Depress Anxiety, 32, pp.262~269 (2015)
3. Zuckerman H, "Recognition and treatment of cognitive dysfunction in major depressive disorder", Front Psychiatry, 9, pp.655~ (2018)
4. Chiara Fabbri, "Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future", Clinical Psychopharmacology and Neuroscience, 18(1), pp.1~9 (2020), 대한정신약물학회[DOI]
5. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
6. Crown WH, "The impact of treatment-resistant depression on health care utilization and costs", J Clin Psychiatry, 63, pp.963~971 (2002)
7. Nelson JC, "Augmentation treatment in major depressive disorder : focus on aripiprazole", Neuropsychiatr Dis Treat, 4, pp.937~948 (2008)
8. Chiara Fabbri, "How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach", Clinical Psychopharmacology and Neuroscience, 18(4), pp.484~492 (2020), 대한정신약물학회[DOI]
9. Thase ME, "Psychopharmacology: the fourth generation of progress", pp.1081~1097 (1995), Raven Press
10. Chen LC, "Antidepressant resistance in adolescents with major depressive disorder : a nationwide longitudinal study", J Affect Disord, 262, pp.293~297 (2020)
11. McIntosh D, "Adult ADHD and comorbid depression : a consensus-derived diagnostic algorithm for ADHD", Neuropsychiatr Dis Treat, 5, pp.137~150 (2009)
12. Faraone SV, "What is the prevalence of adult ADHD? Results of a population screen of 966 adults", J Atten Disord, 9, pp.384~391 (2005)
13. Kessler RC, "The prevalence and correlates of adult ADHD in the United States : results from the National Comorbidity Survey Replication", Am J Psychiatry, 163, pp.716~723 (2006)
14. Adler LA, "Differential diagnosis of attention-deficit", hyperactivity disorder and comorbid conditions, 2006, pp.13, 1~14
15. Sobanski E, "Psychiatric comorbidity in adults with attentiondeficit", hyperactivity disorder (ADHD), 2006, pp.256(Suppl 1), i26~i31
16. Torgersen T, "ADHD in adults : a study of clinical characteristics, impairment and comorbidity", Nord J Psychiatry, 60, pp.38~43 (2006)
17. Bond DJ, "The Canadian Network for Mood and Anxiety Treatments(CANMAT)task force recommendations for the management of patients with mood disorders and comorbid attention-deficit", hyperactivity disorder, 2012, pp.24, 23~37
18. Sternat T, "SSRI treatment response may predict undetected attention deficit hyperactivity disorder in depressed patients", Anxiety and Depression Association of America (ADAA) Annual Conference (2016)
19. Sternat T, "Neurobiology of hedonic tone : the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse", Neuropsychiatr Dis Treat, 12, pp.2149~2164 (2016)
20. Alexander SJ, "Cognitive responses to stress, depression, and anxiety and their relationship to ADHD symptoms in first year psychology students", J Atten Disord, 17, pp.29~37 (2013)
21. Kooij SJ, "European consensus statement on diagnosis and treatment of adult ADHD : The European Network Adult ADHD", BMC Psychiatry, 10, pp.67~ (2010)
22. Ginsberg Y, "Underdiagnosis of attention-deficit", hyperactivity disorder in adult patients : a review of the literature, 2014, pp.16, PCC.13r016~
23. Zetterqvist J, "Stimulant and non-stimulant attention deficit", hyperactivity disorder drug use : total population study of trends and discontinuation patterns 2006-2009, 2013, pp.128, 70~77
24. Gabriel A, "Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety(GA) : an open-label study", Atten Defic Hyperact Disord, 3, pp.319~326 (2011)
25. Bech P, "Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing", Psychother Psychosom, 79, pp.331~338 (2010)
26. Miller IW, "The modified Hamilton Rating Scale for Depression : reliability and validity", Psychiatry Res, 14, pp.131~142 (1985)
27. Simyang Heo, "Clinical Utility of the Korean Version of the WHO Adult AttentionDeficit", Hyperactivity Disorder Self-Report Scale Screener, 2018, pp.15(3), 325~329[DOI]
28. Sang Won Jeon, "Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study", Clinical Psychopharmacology and Neuroscience, 15(1), pp.28~34 (2017), 대한정신약물학회[DOI]
29. 박준영, "한국판 Sheehan Disability Scale의 신뢰도와 타당도 연구", Korean Journal of Clinical Psychology, 29(1), pp.73~81 (2010), 한국임상심리학회[DOI]
30. Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand Suppl, 334, pp.1~100 (1987)
31. Chang Z, "Medication for attention-deficit", hyperactivity disorder and risk for depression : a nationwide longitudinal cohort study, 2016, pp.80, 916~922
32. Findling RL, "Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults : a case series", J Child Adolesc Psychopharmacol, 6, pp.165~175 (1996)
33. Gammon GD, "Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder", J Child Adolesc Psychopharmacol, 3, pp.1~10 (1993)
34. Patkar AA, "A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression", J Clin Psychopharmacol, 26, pp.653~656 (2006)
35. Carpenter LL, "Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants", J Clin Psychiatry, 66, pp.1234~1238 (2005)
36. Kratochvil CJ, "Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms", J Am Acad Child Adolesc Psychiatry, 44, pp.915~924 (2005)
37. Bushe C, "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit", hyperactivity disorder in adult patients, 2016, pp.30, 444~458
38. Zimmerman M, "A clinically useful depression outcome scale", Compr Psychiatry, 49, pp.131~140 (2008)
39. Zimmerman M, "Validity of a self-report depression symptom scale for identifying remission in depressed outpatients", Compr Psychiatry, 47, pp.185~188 (2006)

관련 논문AI추천